Emmaus Life Sciences EMMA

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing, and sale of innovative treatments and therapies primarily for rare and orphan diseases. The company focuses on addressing unmet medical needs in underserved patient populations. Its core activity centers on the commercialization of Endari®, a prescription-grade L-glutamine oral powder approved for sickle cell disease.

Emmaus Life Sciences, Inc. generates revenue primarily through the sale of Endari® in the United States and international markets. In the U. S., the company sells Endari® through nonexclusive distributors including major specialty pharmacy and healthcare distributors. In the Middle East and North Africa region, revenue comes from exclusive distribution agreements with local partners. Additionally, the company has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., which includes an upfront cash payment, ongoing royalties based on net sales, and future milestone payments contingent upon regulatory approvals and commercialization milestones.

The company operates through the following segments:

• Sickle Cell Disease Therapy: This segment focuses on the development, regulatory approval, manufacturing, and commercialization of Endari® for the treatment of sickle cell disease. Endari® is the company’s only FDA-approved product and is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. The trademarked name Endari® is central to this segment’s identity and commercial strategy.
• Licensing and Partnership Development: This segment involves negotiating and managing licensing agreements with third parties for the commercialization of company-owned technologies and products. Under the License Agreement with NeoImmuneTech, Inc., Emmaus Life Sciences, Inc. granted an exclusive license to market, sell, and distribute Endari® in the United States, its territories and possessions, and Canada. The agreement includes provisions for upfront payments, royalties, sublicensing revenue, and an exclusive supply arrangement whereby Emmaus supplies the product to NeoImmuneTech at a cost-plus margin.

Emmaus Life Sciences, Inc. operates in a competitive biopharmaceutical landscape marked by several FDA-approved therapies for sickle cell disease, including hydroxyurea, voxelotor (Oxbryta™), and crizanlizumab (Adakveo®). The company differentiates Endari® through its mechanism of action enhancing nicotinamide adenine dinucleotide synthesis to reduce oxidative stress in sickle red blood cells, supported by clinical trial data showing a 25% reduction in sickle cell crises and a 33% reduction in hospitalizations. Despite losing orphan drug marketing exclusivity in the U. S. in July 2024, which led to the entry of a generic version by ANI Pharmaceuticals, Inc., Emmaus maintains a position through its established distributor network, reimbursement access via Medicare and Medicaid, and ongoing real-world evidence studies to validate long-term effectiveness.

Emmaus Life Sciences, Inc. serves patients with sickle cell disease, primarily adults and pediatric individuals aged five years and older. The product is distributed through hospitals, specialty pharmacies, and retail pharmacies nationwide in the United States via agreements with leading distributors such as ASD Healthcare (a Cencora company), McKesson Plasma and Biologics LLC, Cardinal Health 108 LLC, and CVS Caremark L. L. C. Internationally, the company reaches patients through exclusive distribution partners in the Gulf Cooperation Council countries and other Middle East and North Africa nations where marketing authorizations have been secured.